Incyte Corporation Closes Recruitment For NX-1207 Phase 2 Prostate Cancer Trial

Published: Jan 13, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HASBROUCK HEIGHTS, N.J., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that recruitment is being closed for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line study results are expected to be available approximately 6-8 weeks after completion of enrollment.

Help employers find you! Check out all the jobs and post your resume.

Back to news